Mary Wilson
Well-known member
May 14, 2022
UPDATED: May 14, 2022 08:04 IST
Ashish Pandey
India’s first indigenous mRNA (Messenger RNA) vaccine technology to fight against Covid-19 has been developed by the Centre for Cellular and Molecular Biology (CCMB) and Council Of Scientific And Industrial Research (CSIR).
... This mRNA in the host cells gives rise to the microbial protein or a part of it, which trains the immune system to evade it when the real infection happens with the same live microorganism.
CSIR-Centre for Cellular and Molecular Biology (CCMB) is leading the development of mRNA vaccine technology in India.
... “We observed robust immune responses against SARS-CoV-2 Spike protein in mice, upon administration of two doses of the mRNA. The anti-Spike antibodies generated were found to be more than 90% efficient in preventing the human ACE2 receptor binding to the coronavirus,” said Dr Rajesh Iyer, a scientist involved in the project.
Currently, the mRNA vaccine candidate is undergoing preclinical challenge studies to evaluate its efficacy to protect against live virus infection.
... we lack the potent mRNA vaccine technology, as developed by Moderna or Pfizer/BioNtech to combat COVID-19 in the U.S.A and Europe. The developed technology is different from the mRNA vaccine being developed by Gennova Bio, which is based on self-replicating RNA,” said Dr Madhusudhana Rao, CEO, AIC-CCM.
He added that the AIC-CCMB team were able to establish mRNA vaccine technology and develop a home-grown mRNA vaccine candidate against SARS-CoV-2 in less than a year since the inception of the project. ...
https://www.indiatoday.in/coronavir...-technology-fight-covid-19-1949298-2022-05-14
UPDATED: May 14, 2022 08:04 IST
Ashish Pandey
India’s first indigenous mRNA (Messenger RNA) vaccine technology to fight against Covid-19 has been developed by the Centre for Cellular and Molecular Biology (CCMB) and Council Of Scientific And Industrial Research (CSIR).
... This mRNA in the host cells gives rise to the microbial protein or a part of it, which trains the immune system to evade it when the real infection happens with the same live microorganism.
CSIR-Centre for Cellular and Molecular Biology (CCMB) is leading the development of mRNA vaccine technology in India.
... “We observed robust immune responses against SARS-CoV-2 Spike protein in mice, upon administration of two doses of the mRNA. The anti-Spike antibodies generated were found to be more than 90% efficient in preventing the human ACE2 receptor binding to the coronavirus,” said Dr Rajesh Iyer, a scientist involved in the project.
Currently, the mRNA vaccine candidate is undergoing preclinical challenge studies to evaluate its efficacy to protect against live virus infection.
... we lack the potent mRNA vaccine technology, as developed by Moderna or Pfizer/BioNtech to combat COVID-19 in the U.S.A and Europe. The developed technology is different from the mRNA vaccine being developed by Gennova Bio, which is based on self-replicating RNA,” said Dr Madhusudhana Rao, CEO, AIC-CCM.
He added that the AIC-CCMB team were able to establish mRNA vaccine technology and develop a home-grown mRNA vaccine candidate against SARS-CoV-2 in less than a year since the inception of the project. ...
https://www.indiatoday.in/coronavir...-technology-fight-covid-19-1949298-2022-05-14
